OR WAIT null SECS
© 2021 MJH Life Sciences and Pharmaceutical Technology. All rights reserved.
© 2021 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
July 16, 2021
The new lab near Continuus Pharmaceutical’s current facilities in Massachusetts will expand the company’s process development capabilities to high-potency drugs.
July 12, 2021
UltraBurst has a high disintegration speed, which is for all market segments, from prescriptions to nutraceuticals.
April 26, 2021
Lonza’s new complex will occupy 2000 m2 of the facility with six levels of manufacturing space and will provide room for future small-molecule technologies expansion.
April 03, 2021
Intensified and distributed manufacturing approaches create flexible, local capacity.
March 22, 2021
The companies will work to discover and develop RNA-targeting small-molecule therapeutics for difficult-to-address indications.
March 15, 2021
Continuus Pharmaceuticals is building the first GMP facility using integrated continuous manufacturing technology for end-to-end production of small-molecule APIs and finished dosage forms.
March 08, 2021
USP is collaborating with Phlow to build a new lab that will develop test methods and standards to facilitate broader adoption of continuous manufacturing.
March 02, 2021
FDA moves recommended timeline for API and drug manufacturers to assess impurity risks to March 31, 2021.
February 18, 2021
The deal expands Wavelength’s drug substance manufacturing footprint and its API CDMO business.
February 16, 2021
The increased services will work in conjunction with the site’s SimpliFiH Solutions first-in-human services, which includes phase-appropriate drug substance and drug product development and manufacturing.